Avacincaptad Pegol for Geographic Atrophy Secondary to Age-Related Macular Degeneration: Two-Year Efficacy and Safety Results from the GATHER2 Phase 3 Trial.

چکیده

Avacincaptad pegol (ACP) is a pegylated RNA aptamer that inhibits complement C5. The efficacy and safety of ACP 2 mg was investigated in GATHER2, with positive year 1 results published. Herein, 2-year results are reported. Phase 3, randomized, sham-controlled study (ClinicalTrials.gov identifier,…

متن کامل چکیده در سایت ناشر در دسترس است.

موضوعات مرتبط

• تصویربرداری و تشخیص
• درمان های ضد VEGF
• دژنراسیون ماکولا